These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 22396610)

  • 1. A human challenge model for Mycobacterium tuberculosis using Mycobacterium bovis bacille Calmette-Guerin.
    Minassian AM; Satti I; Poulton ID; Meyer J; Hill AV; McShane H
    J Infect Dis; 2012 Apr; 205(7):1035-42. PubMed ID: 22396610
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimization of a Human Bacille Calmette-Guérin Challenge Model: A Tool to Evaluate Antimycobacterial Immunity.
    Minhinnick A; Harris S; Wilkie M; Peter J; Stockdale L; Manjaly-Thomas ZR; Vermaak S; Satti I; Moss P; McShane H
    J Infect Dis; 2016 Mar; 213(5):824-30. PubMed ID: 26450421
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of a human BCG challenge model to assess antimycobacterial immunity induced by BCG and a candidate tuberculosis vaccine, MVA85A, alone and in combination.
    Harris SA; Meyer J; Satti I; Marsay L; Poulton ID; Tanner R; Minassian AM; Fletcher HA; McShane H
    J Infect Dis; 2014 Apr; 209(8):1259-68. PubMed ID: 24273174
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune responses of white-tailed deer (Odocoileus virginianus) to Mycobacterium bovis BCG vaccination.
    Waters WR; Palmer MV; Whipple DL; Slaughter RE; Jones SL
    J Wildl Dis; 2004 Jan; 40(1):66-78. PubMed ID: 15137490
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A new tool for tuberculosis vaccine screening: Ex vivo Mycobacterial Growth Inhibition Assay indicates BCG-mediated protection in a murine model of tuberculosis.
    Zelmer A; Tanner R; Stylianou E; Damelang T; Morris S; Izzo A; Williams A; Sharpe S; Pepponi I; Walker B; Hokey DA; McShane H; Brennan M; Fletcher H
    BMC Infect Dis; 2016 Aug; 16():412. PubMed ID: 27519524
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of a non-human primate BCG infection model for the evaluation of candidate tuberculosis vaccines.
    Harris SA; White A; Stockdale L; Tanner R; Sibley L; Sarfas C; Meyer J; Peter J; O'Shea MK; Manjaly Thomas ZR; Hamidi A; Satti I; Dennis MJ; McShane H; Sharpe S
    Tuberculosis (Edinb); 2018 Jan; 108():99-105. PubMed ID: 29523335
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Goats primed with Mycobacterium bovis BCG and boosted with a recombinant adenovirus expressing Ag85A show enhanced protection against tuberculosis.
    Pérez de Val B; Villarreal-Ramos B; Nofrarías M; López-Soria S; Romera N; Singh M; Abad FX; Xing Z; Vordermeier HM; Domingo M
    Clin Vaccine Immunol; 2012 Sep; 19(9):1339-47. PubMed ID: 22761299
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety of a controlled human infection model of tuberculosis with aerosolised, live-attenuated Mycobacterium bovis BCG versus intradermal BCG in BCG-naive adults in the UK: a dose-escalation, randomised, controlled, phase 1 trial.
    Satti I; Marshall JL; Harris SA; Wittenberg R; Tanner R; Lopez Ramon R; Wilkie M; Ramos Lopez F; Riste M; Wright D; Peralta Alvarez MP; Williams N; Morrison H; Stylianou E; Folegatti P; Jenkin D; Vermaak S; Rask L; Cabrera Puig I; Powell Doherty R; Lawrie A; Moss P; Hinks T; Bettinson H; McShane H
    Lancet Infect Dis; 2024 Aug; 24(8):909-921. PubMed ID: 38621405
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Boosting of cellular immunity against Mycobacterium tuberculosis and modulation of skin cytokine responses in healthy human volunteers by Mycobacterium bovis BCG substrain Moreau Rio de Janeiro oral vaccine.
    Cosgrove CA; Castello-Branco LR; Hussell T; Sexton A; Giemza R; Phillips R; Williams A; Griffin GE; Dougan G; Lewis DJ
    Infect Immun; 2006 Apr; 74(4):2449-52. PubMed ID: 16552077
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recombinant bacille Calmette-Guerin coexpressing Ag85b, CFP10, and interleukin-12 elicits effective protection against Mycobacterium tuberculosis.
    Chen YY; Lin CW; Huang WF; Chang JR; Su IJ; Hsu CH; Cheng HY; Hsu SC; Dou HY
    J Microbiol Immunol Infect; 2017 Feb; 50(1):90-96. PubMed ID: 25732698
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of advanced age on Mycobacterium bovis BCG vaccination in guinea pigs aerogenically infected with Mycobacterium tuberculosis.
    Komine-Aizawa S; Yamazaki T; Yamazaki T; Hattori S; Miyamoto Y; Yamamoto N; Haga S; Sugitani M; Honda M; Hayakawa S; Yamamoto S
    Clin Vaccine Immunol; 2010 Oct; 17(10):1500-6. PubMed ID: 20685935
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protection against bovine tuberculosis induced by oral vaccination of cattle with Mycobacterium bovis BCG is not enhanced by co-administration of mycobacterial protein vaccines.
    Wedlock DN; Aldwell FE; Vordermeier HM; Hewinson RG; Buddle BM
    Vet Immunol Immunopathol; 2011 Dec; 144(3-4):220-7. PubMed ID: 22005585
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the protective efficacy of bacille calmette-Guérin vaccination against aerosol challenge with Mycobacterium tuberculosis and Mycobacterium bovis.
    Williams A; Davies A; Marsh PD; Chambers MA; Hewinson RG
    Clin Infect Dis; 2000 Jun; 30 Suppl 3():S299-301. PubMed ID: 10875804
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IFN-
    Rivas-Santiago CE; Guerrero GG
    Biomed Res Int; 2017; 2017():8796760. PubMed ID: 29090221
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase 1 Open-Label Dose Escalation Trial for the Development of a Human Bacillus Calmette-Guérin Challenge Model for Assessment of Tuberculosis Immunity In Vivo.
    Blazevic A; Edwards RL; Xia M; Eickhoff CS; Hamzabegovic F; Meza KA; Ning H; Tennant J; Mosby KJ; Ritchie JC; Girmay T; Lai L; McCullough M; Beck A; Kelley C; Edupuganti S; Kabbani S; Buchanan W; Makhene MK; Voronca D; Cherikh S; Goll JB; Rouphael NG; Mulligan MJ; Hoft DF
    J Infect Dis; 2024 May; 229(5):1498-1508. PubMed ID: 38019956
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MVA.85A boosting of BCG and an attenuated, phoP deficient M. tuberculosis vaccine both show protective efficacy against tuberculosis in rhesus macaques.
    Verreck FA; Vervenne RA; Kondova I; van Kralingen KW; Remarque EJ; Braskamp G; van der Werff NM; Kersbergen A; Ottenhoff TH; Heidt PJ; Gilbert SC; Gicquel B; Hill AV; Martin C; McShane H; Thomas AW
    PLoS One; 2009; 4(4):e5264. PubMed ID: 19367339
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gene expression and cytokine profile correlate with mycobacterial growth in a human BCG challenge model.
    Matsumiya M; Satti I; Chomka A; Harris SA; Stockdale L; Meyer J; Fletcher HA; McShane H
    J Infect Dis; 2015 May; 211(9):1499-509. PubMed ID: 25381367
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical development of an in vivo BCG challenge model for testing candidate TB vaccine efficacy.
    Minassian AM; Ronan EO; Poyntz H; Hill AV; McShane H
    PLoS One; 2011; 6(5):e19840. PubMed ID: 21629699
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity and protective efficacy conferred by a novel recombinant Mycobacterium bovis bacillus Calmette-Guérin strain expressing interleukin-12p70 of human cytokine and Ag85A of Mycobacterium tuberculosis fusion protein.
    Deng YH; He HY; Zhang FJ
    Scand J Immunol; 2013 Dec; 78(6):497-506. PubMed ID: 24283772
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cell wall skeleton of Mycobacterium bovis BCG enhances the vaccine potential of antigen 85B against tuberculosis by inducing Th1 and Th17 responses.
    Back YW; Choi S; Choi HG; Shin KW; Son YJ; Paik TH; Kim HJ
    PLoS One; 2019; 14(3):e0213536. PubMed ID: 30849108
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.